Is TransMedics Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for TransMedics Group, Inc. moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 96, an EV to EBITDA of 66.22, and a PEG ratio of 0.53, which suggests a more favorable growth outlook relative to its price.
In comparison to peers, TransMedics has a P/E of 50.23, while Integer Holdings Corp. is considered very expensive at a P/E of 41.17, and CONMED Corp. is attractive with a P/E of 19.96. Notably, TransMedics has outperformed the S&P 500 significantly over the 3-year and 5-year periods, with returns of 189.30% and 770.04%, respectively, reinforcing its fair valuation amidst a volatile market.